Literature DB >> 23070056

Therapeutic role of toll-like receptor modification in cardiovascular dysfunction.

Ali Navi1, Hemanshu Patel, Sidney Shaw, Daryll Baker, Janice Tsui.   

Abstract

Toll-like receptors (TLR) are key pattern recognition receptors in the innate immune system. The TLR-mediated immune response against pathogens is usually protective however inappropriate TLR activation may lead to excessive tissue damage. It is well recognised that TLRs respond to a variety of endogenous as well as exogenous ligands. By responding to endogenous ligands that are exposed during cellular damage, TLRs have been implicated in a range of pathological conditions associated with cardiovascular dysfunction. Increasing knowledge on the mechanisms involved in TLR signalling has encouraged the exploration of therapeutic pharmacological modulation of TLR activation in conditions such as atherosclerosis, ischaemic heart disease, heart failure and ischaemic reperfusion injury. The aim of this review is to explore the translational potentials of TLR modification in cardiovascular dysfunction, where these agents have been studied.
Copyright © 2012 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 23070056     DOI: 10.1016/j.vph.2012.10.001

Source DB:  PubMed          Journal:  Vascul Pharmacol        ISSN: 1537-1891            Impact factor:   5.773


  9 in total

Review 1.  International Union of Basic and Clinical Pharmacology. XCVI. Pattern recognition receptors in health and disease.

Authors:  Clare E Bryant; Selinda Orr; Brian Ferguson; Martyn F Symmons; Joseph P Boyle; Tom P Monie
Journal:  Pharmacol Rev       Date:  2015       Impact factor: 25.468

2.  Are the leukocyte telomere length attrition and telomerase activity alteration potential predictor biomarkers for sporadic TAA in aged individuals?

Authors:  Carmela R Balistreri; Calogera Pisano; Adriana Martorana; Oreste F Triolo; Domenico Lio; Giuseppina Candore; Giovanni Ruvolo
Journal:  Age (Dordr)       Date:  2014-08-17

Review 3.  Toll-like Receptors in the Vascular System: Sensing the Dangers Within.

Authors:  Styliani Goulopoulou; Cameron G McCarthy; R Clinton Webb
Journal:  Pharmacol Rev       Date:  2016-01       Impact factor: 25.468

4.  Toll-like receptors and cutaneous melanoma.

Authors:  Ilaria Coati; Serena Miotto; Irene Zanetti; Mauro Alaibac
Journal:  Oncol Lett       Date:  2016-09-21       Impact factor: 2.967

5.  Toll-like receptors 2 and 4 modulate autonomic control of heart rate and energy metabolism.

Authors:  Eitan Okun; Kathleen J Griffioen; Sarah Rothman; Ruiqian Wan; Wei-Na Cong; Rafael De Cabo; Alejandro Martin-Montalvo; Andrew Levette; Stuart Maudsley; Bronwen Martin; Thiruma Valavan Arumugam; Mark P Mattson
Journal:  Brain Behav Immun       Date:  2013-10-18       Impact factor: 7.217

Review 6.  TWEAK-Fn14 Cytokine-Receptor Axis: A New Player of Myocardial Remodeling and Cardiac Failure.

Authors:  Tatyana Novoyatleva; Amna Sajjad; Felix B Engel
Journal:  Front Immunol       Date:  2014-02-11       Impact factor: 7.561

7.  Can the TLR-4-mediated signaling pathway be "a key inflammatory promoter for sporadic TAA"?

Authors:  Giovanni Ruvolo; Calogera Pisano; Giuseppina Candore; Domenico Lio; Cesira Palmeri; Emiliano Maresi; Carmela R Balistreri
Journal:  Mediators Inflamm       Date:  2014-07-10       Impact factor: 4.711

8.  Epidermal growth factor effect on lipopolysaccharide-induced inflammation in fibroblasts derived from diabetic foot ulcer.

Authors:  Yssel Mendoza-Marí; Ariana García-Ojalvo; Maday Fernández-Mayola; Nadia Rodríguez-Rodríguez; Indira Martinez-Jimenez; Jorge Berlanga-Acosta
Journal:  Scars Burn Heal       Date:  2022-02-18

9.  Association of a common TLR-6 polymorphism with coronary artery disease - implications for healthy ageing?

Authors:  Lutz Hamann; Alexander Koch; Saubashya Sur; Nadja Hoefer; Christiane Glaeser; Susanne Schulz; Michael Gross; Andre Franke; Ute Nöthlings; Kai Zacharowski; Ralf R Schumann
Journal:  Immun Ageing       Date:  2013-10-30       Impact factor: 6.400

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.